Browse By Model Organism Result Page of OvirusTdb

The total number of records retrieved from this search are 100. Click on ID to see further detail.
IDVirus nameVirus strainVirus genome typeVirus familyVirus genome modificationVirus aloneVirus in combination with drug/radiationImmune gene insertion in viral genomeSource of cell lineOrigin of cell lineCell lineConcentration of cell lineIn-vitro toxicityAssayIn-vitro virus concentrationIn-vitro resultModel organismIn-vivo virus concentrationIn-vivo toxicityIn-vivo resultMode of deliveryPathway inducedImmunogenic effectClinical trialPMID
OV_192Herpes simplex virusrQNestin34.5DNAHerpesviridaeDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoterYesNoNoNANANANANANANANAFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells5.0E+5 PFU (on 5 day) in total 8 miceNA 40% mice survived on 28th dayIntratumorallyNANANA26524593
OV_193Herpes simplex virusrQNestin34.5DNAHerpesviridaeDeletion mutant for both copies of gamma 34.5 gene and ICP6 gene, re-addition of 34.5 gene under nestin promoterNoVirus in combination with tubastatin A (TA) at a dose of 1.3 mg per kg body weight (4, 5, 6, 7 and 8 days after tumor implantation)NoNANANANANANANANAFemale athymic nu/nu mice injected intracranially with GBM30 cells 1.0E+5 cells5.0E+5 PFU (on 5 day) in total 8 miceNA 80% mice survived on 28th dayIntratumorallyNANANA26524593
OV_357AdenovirusAdhz60DNAAdenoviridaeE1b-deleted mutantYesNoNoNANANANANANANANAAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)1.0E+9 pfu (every 3 days for at total 4 treatments)NA 41% smaller tumor size compared to the negative control virus AdLacZIntratumorallyNANANA26561948
OV_358AdenovirusAdhz60DNAAdenoviridaeE1b-deleted mutantNoVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive daysNoNANANANANANANANAAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)1.0E+9 pfu (every 3 days for at total 4 treatments)NA 70% smaller tumor size compared to the negative control virus AdLacZIntratumorallyJNK activation induces autophagyNANA26561948
OV_359AdenovirusAdLacZDNAAdenoviridaeE1/E3-deleted mutantNoVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive daysNoNANANANANANANANAAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)1.0E+9 pfu (every 3 days for at total 4 treatments)NA 30% smaller tumor size compared to the negative control virus AdLacZIntratumorallyJNK activation induces autophagyNANA26561948
OV_376Herpes simplex virusSeprehvir (HSV1716)DNAHerpesviridaeΔγ134.5 attenuated virus mutantYesNoNoNANANANANANANANAAthymic nude mice (subcutaneously xenografted with CHLA-20)1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)NA 42% mice survivedIntratumorallyNANANA26583803
OV_377Herpes simplex virusSeprehvir (HSV1716)DNAHerpesviridaeΔγ134.5 attenuated virus mutantYesNoNoNANANANANANANANAAthymic nude mice (subcutaneously xenografted with CHP-123)1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)NA 63% mice survivedIntratumorallyNANANA26583803
OV_378Herpes simplex virusSeprehvir (HSV1716)DNAHerpesviridaeΔγ134.5 attenuated virus mutantYesNoNoNANANANANANANANAAthymic nude mice (subcutaneously xenografted with SK-N-AS)1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)NA 0% mice survivedIntratumorallyNANANA26583803
OV_379Herpes simplex virusSeprehvir (HSV1716)DNAHerpesviridaeΔγ134.5 attenuated virus mutantYesNoNoNANANANANANANANAAthymic nude mice (subcutaneously xenografted with SK-N-BE(2))1.0E+7 pfu in 100 μL (on days 0, 2 and 4 after the tumor mass reached 150–300 mm³)NA 18% mice survivedIntratumorallyNANANA26583803
OV_392Vaccinia virusGLV-1h68DNAPoxviridaeNoneYesNoNoNANANANANANANANAHomozygous athymic female nude mice (subcutaneously injected with KMC-1 cells suspended in 50 μl Matrigel)1.0E+7 PFUNA Reduction in tumor volume to 30 cubic millimeter compared to control 200 cubic millimeter after 15 daysIntratumorallyNANANA26584530
OV_749AdenovirusAdAFPp-E1ADNAAdenoviridaeThe viral mutant with E1A gene driven by AFP promoterYesNoNoNANANANANANANANAHepG2 orthotopic liver xenograft tumor in Balb/c athymic nudeNANA Reduction in tumor weight to 0.2 g compared to control 0.75 g after 18 daysintravenouslyNANANA27450327
OV_750AdenovirusAdAFPp-E1A-122DNAAdenoviridaeThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expressionYesNoNoNANANANANANANANAHepG2 orthotopic liver xenograft tumor in Balb/c athymic nudeNANA Reduction in tumor weight to 0.2 g compared to control 0.75 g after 18 daysintravenouslyNANANA27450327
OV_751AdenovirusAdTrackDNAAdenoviridaeNoneYesNoNoNANANANANANANANAHepG2 orthotopic liver xenograft tumor in Balb/c athymic nudeNANA Reduction in tumor weight to 0.85 g compared to control 0.75 g after 18 daysintravenouslyNANANA27450327
OV_752AdenovirusAdAFPp-E1A-122DNAAdenoviridaeThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expressionYesNoNoNANANANANANANANAHepG2 subcutaneous liver xenograft tumor in Balb/c athymic nudeNANA Reduction in tumor volume to 0.8 cubic centimeter compared to control 2.4 cubic centimeter after 15 daysintravenouslyNANANA27450327
OV_838Herpes simplex virusHSV-G207DNAHerpesviridaeDeletion mutant of both copies of gamma 34.5 geneYesNoNoNANANANANANANANAAthymic rat xenograft model for C85 cell line1.0E+7 pfu NA No responseDirect injectionNANANA10428757
OV_839Herpes simplex virusHSV-G207DNAHerpesviridaeDeletion mutant of both copies of gamma 34.5 geneYesNoNoNANANANANANANANAAthymic rat xenograft model for C86 cell line1.0E+7 pfu NA 4 xenograft model shows partial reduction and 2 shows complete reduction (50% reduction)Direct injectionNANANA10428757
OV_840Herpes simplex virusHSV-G207DNAHerpesviridaeDeletion mutant of both copies of gamma 34.5 geneYesNoNoNANANANANANANANAAthymic rat xenograft model for HCT8 cell line1.0E+7 pfu NA 4 xenograft model shows complete reduction and 4 shows partial reduction (complete reduction)Direct injectionNANANA10428757
OV_858Measles virusMV-EdmRNAParamyxoviridaeRecombinant expressing a peptideYesNovirus expressing a marker peptide (MV-hCEA)NaturalNANANANANANANAFemale athymic mouse xenograft model for SKOV3 cell line1.0E+7 pfu/mlNA Median survival time increased by >105 dayssubcutaneousNANANA12183422
OV_859Measles virusMV-EdmRNAParamyxoviridaeRecombinant expressing a peptideYesNovirus expressing a marker peptide (MV-hCEA)NaturalNANANANANANANAFemale athymic mouse xenograft model for SKOV3 cell line10⁷pfu/mlNA Median survival time increased by >80 daysintraperitonialNANANA12183422
OV_897Herpes simplex virusMutantDNAHerpesviridaeDeletion mutant for Gamma 34.5YesNoNoATCCNANANANANANANAHsd athymic nude mice xenograft for Hep 3B cancer cell line1.0E+7 pfu NA Complete reduction in tumor nodes after 4 weeksintraperitonialNANANA12788648
OV_1103AdenovirusZD55-IL-24DNAAdenoviridaeAdenovirus expressing ZD55 gene and IL-24 geneYesNoExpressing IL-24 geneShanghai cell collectionNANANANANANANAAthymic BALB/c nude mice xenograft for SW620 cell line5.0E+8 cells per wellNA Decrease in tumor volume below 800mm³ as compared to controlIntratumoral injectionApoptosis induction and cspase 3 activationNANA15661558
OV_1104AdenovirusAd-IL-24DNAAdenoviridaeAdenovirus expressing IL-24 geneYesNoExpressing IL-24 geneShanghai cell collectionNANANANANANANAAthymic BALB/c nude mice xenograft for SW620 cell line5.0E+8 cells per wellNA Decrease in tumor volume below 600mm³ as compared to controlIntratumoral injectionApoptosis induction and cspase 3 activationNANA15661558
OV_1105AdenovirusONYX-015DNAAdenoviridaeNoneYesNoNoShanghai cell collectionNANANANANANANAAthymic BALB/c nude mice xenograft for SW620 cell line5.0E+8 cells per wellNA Complete reduction in tumor volumeIntratumoral injectionApoptosis induction and cspase 3 activationNANA15661558
OV_1190AdenovirusICOVIR-5DNAAdenoviridaeNoneNoICOVIR-5 in combination with RAD001 drug (5mg/kg for 5 days)NoATCCHuman glioblastoma cell lineU-87 MGNANANANANAAthymic nude mice xenograft for U87MG cells1.0E+7 pfu NA Complete reduction of tumor after 90 days in 20-40% of animalsNANANANA17557108
OV_1191AdenovirusICOVIR-5DNAAdenoviridaeNoneNoICOVIR-5 in combination with Temozolomide drug (7.5mg/kg for 5 days)NoATCCHuman glioblastoma cell lineU-87 MGNANANANANAAthymic nude mice xenograft for U87MG cells1.0E+7 pfu NA Complete reduction of tumor after 90 days in 20-40% of animalsNANANANA17557108
OV_1665Herpes simplex virusHSV-1DNAHerpesviridaeNoneYesNoVirus expressing vstat120 geneNANANANANANANANAAthymic nude mice, injected with U87deltaEGFR cell line1.0E+5 pfuNA Significant increase in median survival time of miceIntracranialNANANA19844198
OV_1666Herpes simplex virusHSV-1DNAHerpesviridaeNoneYesNoVirus expressing vstat120 geneNANANANANANANANAAthymic nude mice, injected with GlideltaEGFR-H2B-RFP cell line1.5E+6 cellsNA Significant reduction in tumor volume and increase in median survival time of miceSubcutaneouslyNANANA19844198
OV_1915Vaccinia virusGLV-1h68DNAPoxviridaeNoneYesNoNoATCCMalignan small cell canine carcinoma cell lineMTH52cNANANANANAHsd athymic nude mice xenograft for MTH52c cell line5.0E+6 pfuNA Significant decrease in tumor volume after 42 daysNANAVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alphaNA20631910
OV_2063Vaccinia virusGLV-1h68DNAPoxviridaeNoneYesNoNoATCCHuman hepatocellular carcinoma cell linePLCNANANANANAAthymic hsd nude mice xenograft for PLC cell line5.0E+6 pfuReduction in tumor volume below 2000mm compared to control after 45 days No responseNAInduction of apoptosis in cancer cell lineIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2NA21779374
OV_2064Vaccinia virusGLV-1h68DNAPoxviridaeNoneYesNoNoATCCHuman hepatocellular carcinoma cell lineHuh-7NANANANANAAthymic hsd nude mice xenograft for PLC cell line5.0E+6 pfuReduction in tumor volume below 3000mm compared to control after 35 days NAInduction of apoptosis in cancer cell lineIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2NA21779374
OV_2408Vesicular stomatitis virusVSV-Delta-M51-GFPRNARhabdoviridaeDeletion of M51 gene and insertion of GFP geneYesNoNoATCCPancreatic ductal adeonocarcinoma cell lineMIAPaCa-2NANANANANAAthymic mice xenograft for MIA PaCa2 cell line5.0E+7 pfuNA Reduction in tumor weight below 5 mg after 25 daysIntratumoralNADownregulation of IFN-GammaNA22238308
OV_2409Vesicular stomatitis virusVSV-Delta-M51-GFPRNARhabdoviridaeDeletion of M51 gene and insertion of GFP geneYesNoNoATCCPancreatic ductal adeonocarcinoma cell linePANC-1NANANANANAAthymic mice xenograft for MIA PANC-1 cell line5 × 10⁷ pfu NA Reduction in tumor weight below 200 mg after 25 daysIntratumoralNADownregulation of IFN-GammaNA22238308
OV_2410Vesicular stomatitis virusVSV-Delta-M51-GFPRNARhabdoviridaeDeletion of M51 gene and insertion of GFP geneYesNoNoATCCPancreatic ductal adeonocarcinoma cell lineHPAF-IINANANANANAAthymic mice xenograft for HPAF-II cell line5 × 10⁷ pfu NA Reduction in tumor weight below 20 mg after 25 daysIntratumoralNADownregulation of IFN-GammaNA22238308
OV_2411Vesicular stomatitis virusVSV-Delta-M51-GFPRNARhabdoviridaeDeletion of M51 gene and insertion of GFP geneYesNoNoATCCPancreatic ductal adeonocarcinoma cell lineSU.86.86NANANANANAAthymic mice xenograft for U.86.86 cell line5 × 10⁷ pfu NA Reduction in tumor weight below 20 mg after 25 daysIntratumoralNADownregulation of IFN-GammaNA22238308
OV_2526Vaccinia virusGLV-1h151DNAPoxviridaeDeteltion of TK gene and addition of GFP geneYesNoNoATCCHuman pancreatic cancer cell linePANC-1NANANANANAHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)2.0E+6 pfuNA Decrease in tumor volume below 2 after 34 daysIntratumoralNANANA22258815
OV_2527Vaccinia virusGLV-1h151DNAPoxviridaeDeteltion of TK gene and addition of GFP geneYesNoNoATCCHuman pancreatic cancer cell linePANC-1NANANANANAHsd:athymic nude mice xenografted for PANC-1 cell line(2.0E+6 cells)2.0E+6 pfuNA Decrease in tumor volume below 2 after 34 daysIntravenousNANANA22258815
OV_2843Vaccinia viruswild typeDNAPoxviridaeNoneYesNoNoATCCHuman colorectal cancer cell lineHCT-116NANANANANAHsd:athymic nude mice xenograft for HCT-116 (5.0E+6 cells)5.0E+6 pfuNA Significant reduction in tumor volume after 42 daysIntratumoralNANANA23531320
OV_3002PoxvirusCF33-hNISDNAPoxviridaeInsertion of gene encoding human hNISYesNoNoATCCHuman colorectal cancer cell lineHCT-116NANANANANAHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)1.0E+5 pfuNA Complete regression in tumor volume after 55 daysIntratumoralImmunogenicity followed by virus induced cell deathNANA31061881
OV_3003PoxvirusCF33-hNISDNAPoxviridaeInsertion of gene encoding human hNISYesNoNoATCCHuman colorectal cancer cell lineHT-29NANANANANAHsd:athymic nude mice xenograft for HT-29 (5.0E+6 cells)1.0E+5 pfuNA Tumor volume reached 1500mm after day 50IntratumoralImmunogenicity followed by virus induced cell deathNANA31061881
OV_3004PoxvirusCF33-hNISDNAPoxviridaeInsertion of gene encoding human hNISNoVirus in combination with I-131NoATCCHuman colorectal cancer cell lineHCT-116NANANANANAHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)1.0E+4 pfuNA Reduction in tumor volume below 100mm after 55 daysIntravenousImmunogenicity followed by virus induced cell deathNANA31061881
OV_3005PoxvirusCF33-hNISDNAPoxviridaeInsertion of gene encoding human hNISNoVirus in combination with I-131NoATCCHuman colorectal cancer cell lineHT-29NANANANANAHsd:athymic nude mice xenograft for HT-29 (3.0E+9 cells)1.0E+4 pfuNA Reduction in tumor volume below 300mm after 45 daysIntravenousImmunogenicity followed by virus induced cell deathNANA31061881
OV_4108Vaccinia virusVVstrain LIVP 6.1.1DNAPoxviridaeMutant for J2R geneYesNoNoUniversity of colorado, USANANANANANANANAHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)1.0E+7 pfuNA Tumor volume reduced to 1000 mm compared to control 2500mm after 42 daysIntravenousNANANA26205404
OV_4109Vaccinia virusVVstrain GLV-5b451DNAPoxviridaeDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locusYesNoNoUniversity of colorado, USANANANANANANANAHsd athymic nude mice xenograft for STSA-1 cell line (1.0E+6)1.0E+7 pfuNA Tumor volume reduced to 200 mm compared to control 2500mm after 49 daysIntravenousNANANA26205404
OV_4148AdenovirusAduPARE1ADNAAdenoviridaeAddition of E1A gene upstream of uPAR promoterNoVirus in combination with gemcitabine (160mg/kg)NoNANANANANANANANAAthymic nude mice xenograft for BxPC-3 (5.0E+5)5.0E+10 VP per cellNA Median survival time increased from 22 days to 57 days with combined tretamentNAVirus induce apoptosis process leads to cancer cell deathNANA26227809
OV_4149AdenovirusAduPARE1ADNAAdenoviridaeAddition of E1A gene upstream of uPAR promoterNoVirus in combination with gemcitabine (160mg/kg)NoNANANANANANANANAAthymic nude mice xenograft for PANC-1 (5.0E+5)5.0E+10 VP per cellNA Median survival time increased from 37 days to 79.5 days with combined tretamentNAVirus induce apoptosis process leads to cancer cell deathNANA26227809
OV_4190Measles virusMV-lambda-NAPRNAParamyxoviridaeGenetically engineered for expressing human lambda immunoglobulin chainYesNoNoNANANANANANANANAFemale athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)2.0E+6 TCID50NA All mice dead after 100 daysIntravenousVirus induce apoptosis process leads to cancer cell deathVirus and drug both cause induction of IL-24 expressionIn clinical trials26272026
OV_4191Measles virusMV-lambda-NAPRNAParamyxoviridaeGenetically engineered for expressing human lambda immunoglobulin chainNoVirus in combination with Alisertib 30mg/kg for 3 weeksNoNANANANANANANANAFemale athymic nude mice xenograft for MDA-231-lu-P4 (1.0E+6 cells)2.0E+6 TCID50NA Mice median survival time increased to 82.5 days compared to controlIntravenousVirus induce apoptosis process leads to cancer cell deathVirus and drug both cause induction of IL-24 expressionIn clinical trials26272026
OV_4192Measles virusMV-lambda-NAPRNAParamyxoviridaeGenetically engineered for expressing human lambda immunoglobulin chainYesNoNoNANANANANANANANAFemale athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity5.0E+5 TCID50NA Mice median survival increased to 57 daysTransthoracicVirus induce apoptosis process leads to cancer cell deathVirus and drug both cause induction of IL-24 expressionIn clinical trials26272026
OV_4193Measles virusMV-lambda-NAPRNAParamyxoviridaeGenetically engineered for expressing human lambda immunoglobulin chainYesVirus in combination with Alisertib 30mg/kg for 3 weeksNoNANANANANANANANAFemale athymic nude mice xenograft for MDA-231-lu-P4 (2.0E+6), pleural effusion transthoracic cavity5.0E+5 TCID50NA Mice median survival increased to 74 days compared to control 57 daysTransthoracicVirus induce apoptosis process leads to cancer cell deathVirus and drug both cause induction of IL-24 expressionIn clinical trials26272026
OV_4438Vesicular stomatitis virusRdBRNARhabdoviridaeVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linkerYesNoNoNANANANANANANANAmale athymic nude mice xenograft for A549 (1.0E+7)5.0E+9 pfuNA Tumor volume become below 600 cubic millimeter after 71 days compared to control 1000IntratumoralNANANA26430798
OV_4439Vesicular stomatitis virusRdB-1L-VSVGRNARhabdoviridaeVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linkerYesNoNoNANANANANANANANAmale athymic nude mice xenograft for A549 (1.0E+7)5.0E+9 pfuNA Tumor volume become below 100 cubic millimeter after 71 days compared to control 1000IntratumoralNANANA26430798
OV_4440Vesicular stomatitis virusRdBRNARhabdoviridaeVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linkerYesNoNoNANANANANANANANAmale athymic nude mice xenograft for MCF7 (1.0E+7)5.0E+10 pfuNA Tumor volume become below 1500 cubic millimeter after 49 days compared to control 4000IntratumoralNANANA26430798
OV_4441Vesicular stomatitis virusRdB-1L-VSVGRNARhabdoviridaeVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linkerYesNoNoNANANANANANANANAmale athymic nude mice xenograft for MCF7 (1.0E+7)5.0E+10 pfuNA Tumor volume become below 600 cubic millimeter after 49 days compared to control 4000IntratumoralNANANA26430798
OV_4505Newcastle disease viruswild typeRNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic nude mice xenograft for HT1080 (5.0E+6)2.0E+7 pfuNA Tumor volume reduced to 300 cubic mm after 25 days compared to control 800 cubic mmIntratumoralNAInduced expression of Type 1 IFN, NK cells and macrophagesNA27009956
OV_4506Newcastle disease virus73T-S-KmRNAParamyxoviridaeInsertion of HNKMKS sequence in fusogenic site between 111 -116 nucleotideYesNoNoNANANANANANANANAAthymic nude mice xenograft for HT1080 (5.0E+6)2.0E+7 pfuNA Tumor volume reduced to below 100 cubic mm after 25 days compared to control 800 cubic mmIntratumoralNAInduced expression of Type 1 IFN, NK cells and macrophagesNA27009956
OV_4507Newcastle disease virus73T-R-198RNAParamyxoviridaeInsertion of HNRTKR sequence in fusogenic site between 111 -116 nucleotideYesNoNoNANANANANANANANAAthymic nude mice xenograft for HT1080 (5.0E+6)2.0E+7 pfuNA Tumor volume reduced to 300 cubic mm after 25 days compared to control 800 cubic mmIntratumoralNAInduced expression of Type 1 IFN, NK cells and macrophagesNA27009956
OV_4508Newcastle disease virus73T-R-198RNAParamyxoviridaeInsertion of HNRTKR sequence in fusogenic site between 111 -116 nucleotideYesNoNoNANANANANANANANAAthymic nude mice xenograft for HT1080 (5.0E+6)1.0E+8 pfuNA Tumor volume reduced to below 500 cubic mm compared to control 1000 cubic mm after 25 daysIntravenousNAInduced expression of Type 1 IFN, NK cells and macrophagesNA27009956
OV_4631AdenovirusAd5/3-delata 24DNAAdenoviridaeMutation in delta E3 and delta 24 geneYesNoNoNANANANANANANANAFemale athymic nude mice xenograft for UPCI SCC 090 (2.0E+6)3.5E+11 pfuNA Complete ereduction in tumor volume after 30 daysIntratumoralNANANA27086483
OV_4632AdenovirusAd5/3-CB016DNAAdenoviridaeMutation in delta E3 geneYesNoNoNANANANANANANANAFemale athymic nude mice xenograft for UPCI SCC 090 (2.0E+6)3.5E+11 pfuNA Complete ereduction in tumor volume after 30 daysIntratumoralNANANA27086483
OV_4698Herpes simplex virusRAMBODNAHerpesviridaeAntiangiogenic Vstat120 expressing virusYesNoNoNANANANANANANANAAthymic nude mice subcutaneous xenograft for CAL27 (1.5E+7)2.0E+6 pfu on day 7 and 16NA Mice treated with virus shows delayed tumor growth compared to control, one shows complete tumor regressionIntratumoralNAInduce antitumor immune responseNA27119105
OV_4704Herpes simplex virusRAMBODNAHerpesviridaeAntiangiogenic Vstat120 expressing virusNoVirus combination with ATN-224 (0.7 mg/kg/day) an copper chelator showing synergistic effectNoNANANANANANANANAAthymic nude mice xenograft for UM-SCC-74A (1.5E+7)2.0E+6 pfu on day 7NA Increased in survival time and reduction in tumor volume to below 200 cubic mm comapred to control 700 cubic mmIntratumoralNAInduce antitumor immune responseNA27119105
OV_4705Herpes simplex virusRAMBODNAHerpesviridaeAntiangiogenic Vstat120 expressing virusNoVirus combination with ATN-224 (0.7 mg/kg/day) an copper chelator showing synergistic effectNoNANANANANANANANAAthymic nude mice xenograft for CAL27 (1.5E+7)2.0E+6 pfu on day 7NA Increased in survival time and reduction in tumor volume to below 500 cubic mm comapred to control 2000 cubic mmIntratumoralNAInduce antitumor immune responseNA27119105
OV_5184Tanapoxviruswild typeDNAPoxviridaeNoneYesNoNoNANANANANANANANAAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells5.0E+6 pfuNA Reduction in tumor growth 250 compared to 550 after 34 daysIntratumoralNANANA27738905
OV_5185TanapoxvirusTPV-delta15LDNAPoxviridaeDeletion mutant for 15L geneYesNoNoNANANANANANANANAAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells5.0E+6 pfuNA Complete regression in tumor volume compared to 550 after 34 daysIntratumoralNANANA27738905
OV_5186TanapoxvirusTPV-delta66RDNAPoxviridaeDeletion mutant for tk 66ORFYesNoNoNANANANANANANANAAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells5.0E+6 pfuNA Reduction in tumor growth 150 compared to 550 after 34 daysIntratumoralNANANA27738905
OV_5187TanapoxvirusTPV-delta15Ldelta66RDNAPoxviridaeDeletion mutant for 15L gene and tk 66R locusYesNoNoNANANANANANANANAAthymic nude mice CrlNU-Foxn1 xenograft for cellosaurus cell line 5.0E+6 cells5.0E+6 pfuNA Reduction in tumor growth 200 compared to 550 after 34 daysIntratumoralNANANA27738905
OV_5638Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)3.0E+8 pfuNA Complete regrression in tumor in 11 mice from complete 12 (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5639Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)3.0E+8 pfuNA Complete regrression in tumor in 8 mice from complete 9 (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5640Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)3.0E+8 pfuNA Complete regrression in tumor in all mice (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5641Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human ovarian carcinoma PA-1 (10 million)3.0E+8 pfuNA Complete regrression in tumor in all mice (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5642Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human oral carcinoma KB (10 million)3.0E+8 pfuNA Complete reduction in tumor in 7 mice from all 12 treated (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5643Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fmelanoma SKMEL (10 million)3.0E+8 pfuNA Complete reduction in tumor in 5 mice from all 8 treated (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5644Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human lung carcinoma A375 (10 million)3.0E+8 pfuNA Complete reduction in tumor in 5 mice from all 8 treated (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5645Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human lung carcinoma A375 (10 million)3.0E+8 pfuNA Complete regrression in tumor in all mice (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5646Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for humanglioblastoma U87MG (10 million)3.0E+8 pfuNA Complete reduction in tumor in 1 mice from all 9 treated (tumor volume <10mm and >5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5647Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)1.0E+9 pfuNA Complete regression in all tumor bearing mice (tumor volume <8.5 mm and > 5.5)IntravenouslyInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5648Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)3.0E+8 pfuNA Complete regression in all tumor bearing mice (tumor volume <8.5 mm and > 5.5)IntravenouslyInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5649Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)6.0E+7 pfuNA Complete regression in tumor volume in 10 mice out of 11 (tumor volume <8.5 mm and > 5.5)IntravenouslyInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5650Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)2.0E+7 pfuNA Complete regression in tumor volume in 5 mice out of 11 (tumor volume <8.5 mm and > 5.5)IntravenouslyInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5651Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for human fibroblast HT1080 (10 million)2.0E+7 pfuNA Complete regression in tumor volume in 5 mice out of 7 (tumor volume <8.5 mm and > 5.5)IntravenouslyInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5652Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)1.5E+9 pfuNA Complete regression in tumor in 2 mice from total 8 tretated (tumor dimension 8 - 9.5mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5653Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)9.0E+8 pfuNA Complete regression in tumor in 7 mice from total 8 tretated (tumor dimension 8 - 9.5mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5654Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in 3 mice from total 8 tretated (tumor dimension 8 - 9.5mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5655Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)1.5E+9 pfuNA Complete regression in tumor in 2 mice from total 6 tretated (tumor volume <300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5656Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)9.0E+8 pfuNA Complete regression in tumor in 3 mice from total 4 tretated (tumor dimension <300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5657Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in 2 mice from total 6 tretated (tumor volume <300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5658Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in 3 mice from total 5 tretated (tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5659Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in all mice(tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5660Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in 4 mice from total 5 tretated (tumor volume>300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5661Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)1.5E+9 pfuNA Complete regression in tumor in all mice (tumor dimension 10 - 11.5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5662Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete regression in tumor in 6 mice from 7 (tumor dimension 10 - 11.5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5663Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+7 pfuNA Complete regression in tumor in 5 mice from 7 (tumor dimension 10 - 11.5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5664Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+6 pfuNA Complete regression in tumor in 5 mice from 7 (tumor dimension 10 - 11.5 mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5665Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)1.5E+9 pfuNA Complete regression in tumor in all mice (tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5666Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+8 pfuNA Complete reduction in tumor in 6 mice from 7 (tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5667Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+7 pfuNA Complete reduction in tumor in 4 mice from 6 (tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5668Newcastle disease virusNDV-MK107RNAParamyxoviridaeNoneYesNoNoNANANANANANANANAAthymic mice xenograft for A375 (10 million)3.0E+6 pfuNA Complete reduction in tumor in 4 mice from 6 (tumor volume >300mm)IntratumoralInduction of apoptosis by virus infectionInduction of IFN-Gamma productionNAUS7470426
OV_5682Vaccinia virusGLV-1h22DNAPoxviridaeInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectivelyYesNoNoNANANANANANANANAHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)5.0E+6 pfuNA Tumor volume become 261.8mm compared to control 240.8 mm after 33 daysIntravenouslyInduction of apoptosisNANAUS8052968
OV_5683Vaccinia virusGLV-1h68DNAPoxviridaeInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectivelyYesNoNoNANANANANANANANAHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)5.0E+6 pfuNA Tumor volume become 248.4mm compared to control 240.8 mm after 33 daysIntravenouslyInduction of apoptosisNANAUS8052968
OV_5684Vaccinia virusGLV-1h70DNAPoxviridaeInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectivelyYesNoNoNANANANANANANANAHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)5.0E+6 pfuNA Tumor volume become 216.8mm compared to control 240.8 mm after 33 daysIntravenouslyInduction of apoptosisNANAUS8052968